PROTONS VERSUS PHOTONS FOR HEPATOCELLULAR CARCINOMA

  • Research type

    Research Study

  • Full title

    A PHASE III RANDOMIZED TRIAL OF PROTONS VERSUS PHOTONS FOR HEPATOCELLULAR CARCINOMA

  • IRAS ID

    299998

  • Contact name

    Ganesh Radhakrishna

  • Contact email

    g.radhakrishna@nhs.net

  • Sponsor organisation

    NRG Oncology

  • Clinicaltrials.gov Identifier

    NCT03186898

  • Duration of Study in the UK

    12 years, 0 months, 1 days

  • Research summary

    Radiotherapy is a treatment option for patients with Hepatocellular Carcinoma (cancer of the liver) which is confined to and has not spread outside of the liver.

    This trial includes patients with cancer of the liver and it will focus on the differences in survival, disease progression, treatment side effects and quality of life using proton beam therapy or PBT (a newer form of radiotherapy) compared with standard photon or x-ray radiotherapy. PBT uses accelerated protons to deliver radiation and can be directed more precisely to the tumour than standard radiotherapy. This reduces the amount of normal tissue surrounding the tumour receiving radiation that isn’t wanted. We know from international use of PBT that it is a safe treatment and is thought to cause less damage to normal tissues.

    PBT does remain a controversial treatment due to the cost and an unproven benefit in overall survival. However, single arm studies suggest superior results compared with photon radiotherapy studies. This randomised trial will enrol 186 patients (half of the participants will receive PBT & half will receive standard radiotherapy) from a number of international centres and seeks to directly answer if protons are superior to photons. The choice of PBT (protons) or standard radiotherapy (photons) will be decided randomly by computer to minimise bias. In the UK we are aiming to recruit approximately 8 patients who will be treated at The Christie NHS Foundation Trust in Manchester (1 of only 2 PBT centres in the UK). After treatment patients will be followed up regularly for up to 10 years and will have regular blood tests, scans and be asked to complete questionnaires looking at fatigue and quality of life.

    Results of this trial will be presented at international conferences and published in peer reviewed medical journals.

  • REC name

    Yorkshire & The Humber - Sheffield Research Ethics Committee

  • REC reference

    24/YH/0107

  • Date of REC Opinion

    25 Jun 2024

  • REC opinion

    Further Information Favourable Opinion